Home Cart Sign in  
Chemical Structure| 924537-98-4 Chemical Structure| 924537-98-4

Structure of BT-13
CAS No.: 924537-98-4

Chemical Structure| 924537-98-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BT13 acts as direct RetA agonists and interacts with GFRα1 at the allosteric site in GDNF-GFRα1-RetA complex. It was similar to NGF and ARTN in selectively promoting neurite outgrowth from the peptidergic class of adult sensory neurons in culture, but was opposite to ARTN in causing neurite elongation without affecting initiation.

Synonyms: BT-13

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BT-13

CAS No. :924537-98-4
Formula : C23H27F4N3O4S
M.W : 517.54
SMILES Code : FC(F)(F)C1=C(C=CC(F)=C1)C(N(CC2)CCN2C3=C(C=CC(S(=O)(N(CC)CC)=O)=C3)OC)=O
Synonyms :
BT-13
MDL No. :MFCD19950448

Safety of BT-13

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of BT-13

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Adult rat dorsal root ganglion (DRG) sensory neurons 100 ng/ml 24–30 h BT13 promoted neurite growth from peptidergic sensory neurons but did not affect neurite initiation Front Pharmacol. 2017 Jun 21;8:365
MG87RET murine fibroblasts 0.1–50 µM BT13 dose-dependently activated luciferase with EC50=17.4 µM, inducing an 11.6-fold increase in luciferase activity Front Pharmacol. 2017 Jun 21;8:365
RET-knockout embryonic midbrain dopamine neurons 0.1 μM, 1 μM 5 days To assess the effect of BT13 on the survival of RET-knockout dopamine neurons. BT13 failed to influence the survival of RET-knockout embryonic midbrain dopamine neurons. Mov Disord. 2020 Feb;35(2):245-255
Wild-type embryonic midbrain dopamine neurons 0.1 μM, 1 μM 5 days To assess the effect of BT13 on the survival of cultured dopamine neurons. BT13 significantly increased the number of surviving wild-type embryonic midbrain dopamine neurons. Mov Disord. 2020 Feb;35(2):245-255
MG87RET cells 25 μM To evaluate the ability of BT13 to activate RET and signal via GFL receptors. BT13 significantly increased the phosphorylation level of RET in cells expressing GFR α1/RET and GFR α2/RET. Mov Disord. 2020 Feb;35(2):245-255

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Spinal nerve ligation (SNL)-induced experimental neuropathy Subcutaneous injection 20 and 25 mg/kg Administered on post-surgical days 1, 3, 5, 8, 10, and 12 BT13 attenuated mechanical hypersensitivity and reversed injury-induced changes in the expression of sensory neuron markers in dorsal root ganglia Front Pharmacol. 2017 Jun 21;8:365
Mice Not specified Stereotactic injection into the striatum 103.5 μg, 207 μg, 517.5 μg, 776.25 μg Single injection To evaluate the ability of BT13 to activate intracellular signaling cascades in the mouse striatum. BT13 at the dose of 750μg significantly increased phosphorylation of ERK and S6. Mov Disord. 2020 Feb;35(2):245-255

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.93mL

0.39mL

0.19mL

9.66mL

1.93mL

0.97mL

19.32mL

3.86mL

1.93mL

References

 

Historical Records

Categories